Researchers designed peptides and plasmids encoding the mouse homologs of the pembrolizumab and nivolumab programmed cell death 1 ligand 1 (PD-L1) binding regions. The mouse homolog to pembrolizumab was effective at blocking PD-1/PD-L1 in vitro.
[Molecular Therapy]